NANOSTRUCTURED LIPID CARRIERS AS A STRATEGY TO IMPROVE THE IN VITRO SCHISTOSOMIASIS ACTIVITY OF PRAZIQUANTEL

FERNANDA KOLENYAK-SANTOS; CLAUDIA GARNERO; ROSIMEIRE N. DE OLIVEIRA; ANA L. R. DE SOUZA; MARLUS CHORILLI; SILMARA M. ALLEGRETTI; MARCELA R. LONGHI; MARCO V. CHAUD; MARIA P.D GREMIÃO

AMER SCIENTIFIC PUBLISHERS

Lugar: California; Año: 2015 vol. 15 p. 761 - 761

raziquantel (PZQ) is a pyrazinoisoquinoline anthelmintic that was discovered in 1972 by Bayer Germany. Currently, due to its efficacy, PZQ is the drug of choice against all species of Schistosoma. Although widely used, PZQ exhibits low and erratic bioavailability because of its poor water solubility. Nanostructured lipid carriers (NLC), second-generation solid lipid nanoparticles, were developed in the 1990s to improve the bioavailability of poorly water soluble drugs. The aim of this study was to investigate nanostructured lipid carriers as a strategy to improve the efficacy of PZQ in S. mansoni treatment. We prepared NLC2 and NLC4 by adding seventy percent glycerol monostearate (GMS) as the solid lipid, 30% oleic acid (OA) as the liquid lipid and two surfactant systems containing either soybean phosphatidylcholine/poloxamer (PC/P-407) or phosphatidylcholine/Tween 60 (PC/T60), respectively. The carriers were characterized by nuclear magnetic resonance, differential scanning calorimet